6 hrs ago
Daily Dividend Report: K, WWE, AMGN, ETR, AVY, RBC
Kellogg declared a dividend of $0.49 per share on the common stock of the Company.
Fri Jul 25, 2014
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary , today announced that an investigational Phase 3 trial of NEXAVAR tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival .
Thu Jul 24, 2014
Amgen Announces Webcast of 2014 Second Quarter Financial Results
Amgen today announced that it will report its second quarter financial results on Tuesday, July 29, 2014, after the close of the U.S. financial markets.
Wed Jul 23, 2014
IPO Preview: Atara Biotherapeutics
Clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology.
Tue Jul 22, 2014
The Motley Fool
Why Investors Continue to Flee Aegerion Stock
Although it's easy to generate huge commercial expectations for rare disease drugs , many companies report very underwhelming sales figures once the drug is brought to market.
Amgen Can Propel Over $120 With Earnings Right Around The Corner
The company posts successful results for the Phase 3 safety and efficacy testing of AMG 416, their secondary hyperthyroidism product.
Mon Jul 21, 2014
The Motley Fool
Yellen Hates Biotech Stocks! Should You?
Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued.
Colorado BioScience Association Recognizes Amgen Foundation's...
The Colorado BioScience Association is honored to recognize the Amgen Foundation's grant of $25,000 to the Colorado BioScience Institute in support of the Research Experience for Teachers program, in addition to funds provided by others including The Anschutz Foundation.
Biotechs Have Their 'Irrational Exuberance' Moment: Time To Buy More?
Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed.
Sat Jul 19, 2014
The Motley Fool
This Week in Biotech: AbbVie's Five-Leaf Clover and Exelixis' Excellent Results
With the SPDR S&P Biotech Index up 18% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector.
Fri Jul 18, 2014
Amgen: Grappling With The Reality Of Patent Expiries
The prevalence rate is quite high, with limited treatment options available. If authorized, Amgen can exploit the first-mover advantage.
Thu Jul 17, 2014
Amgen Thyroid Drug AMG 416 Succeeds In Late Stage Kidney Patient Trial
Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis Analysis Shows Study Met Primary and All Secondary EndpointsAMG 416 is a Novel Calcimimetic Administered Intravenously /PRNewswire/ -- Amgen today announced that a Phase 3 study ... (more)
Amgen Announces Positive Phase 3 Results for AMG 416 for the...
Amgen today announced that a Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease , receiving hemodialysis, met its primary and all secondary endpoints.
Wed Jul 16, 2014
That Model Genentech, Gilead Sciences, Inc., And Amgen Were Built On - Does It Work Anymore?
"The model is broken." I used to hear that chant from biotech VCs all the time, often accompanied by the thwack of self-flagellation.
Tue Jul 08, 2014
Experimenting With Drugs In The Cloud
A science lab in Mountain View, CA is creating faster and cheaper drug experiments by putting them in the cloud.
Thu Jul 03, 2014
Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector
Large-cap biotech stocks should see healthy second-quarter results driven by strong demand and new products, a Citi analyst said Thursday.
The Motley Fool
Biotech Stocks to Watch Today: AbbVie, Bind Therapeutics, MannKind, and Shire
Let's take a look at today's top stories in biotech and health care. Keep an eye out for AbbVie ( AbbVie still pursuing Shire Despite three rejections so far, AbbVie is reportedly still attempting to convince Shire and its major shareholders that a buyout is in their best interest.
Wed Jul 02, 2014
San Fernando Business Journal
Amgen Leukemia Drug Receives Fast-Track Status
The U.S. Food and Drug Administration has given Breakthrough Therapy Designation status to blinatumomab, a drug in development at Amgen Inc. for treating certain cancers.
Tue Jul 01, 2014
Amgen Wins FDA Breakthrough Therapy Designation For Investigational BiTE
The Breakthrough Therapy Designation was based on the results of a Phase 2 trial of 189 adult patients with Ph- relapsed/refractory B-precursor ALL treated with blinatumomab.
Amgen Receives FDA Breakthrough Therapy Designation For...
Amgen today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to investigational bispecific T cell engager ) antibody blinatumomab, for adults with Philadelphia-negative relapsed/refractory B-precursor acute lymphoblastic leukemia , a rapidly progressing cancer of the blood and bone marrow .